---
url: "https://www.lek.com/leadership/christian-seiffert"
title: "Christian Seiffert | L.E.K. Consulting"
---

[Skip to main content](https://www.lek.com/leadership/christian-seiffert#main-content)

[![L.E.K.](https://www.lek.com/themes/lek/images/new-logo.svg)](https://www.lek.com/ "L.E.K.")

Search

- English
- List additional actions
- [Português](https://www.lek.com/pt-br/lek-brazil)
- [简体中文](https://www.lek.com/zh-hant/lek-china)
- [Deutsch](https://www.lek.com/de/leadership/christian-seiffert)
- [日本語](https://www.lek.com/ja/lek-japan)

# Christian Seiffert

Christian Seiffert is a partner in L.E.K. Consulting’s European Life Sciences practice. He joined L.E.K. as a partner in 2016 and focuses on developing strategies for commercialization, go-to-market and product launch as well as corporate strategy. Christian has extensive consulting experience, and he has provided strategic recommendations to leading pharmaceutical, biotechnology and medical technology organizations for more than 20 years.

Before joining L.E.K., Christian was responsible for running the European consulting business in his role as Managing Director and Regional General Manager at inVentiv Health, a global professional services firm for the biopharmaceutical industry. Prior to that, he was a senior member of Monitor Deloitte’s life science practice in Europe.​

Christian holds an advanced degree in Industrial Engineering and Management Sciences from the Technical University of Karlsruhe and Seville Engineering School (ESI).

### Education

**Graduate:** Masters in Industrial Engineering and Management Sciences, Technical University of Karlsruhe and Seville Engineering School.

![Christian Seiffert, L.E.K. Consulting](https://www.lek.com/sites/default/files/profile-images/christian-seiffert_web.jpg)

### Christian's Expertise

#### Industries

[Life Sciences Consulting](https://www.lek.com/industries/life-sciences-pharma)

[Biotech and Pharmaceuticals](https://www.lek.com/industries/life-sciences-pharma/biotech-pharmaceutical)

[MedTech](https://www.lek.com/industries/medtech)

[Procedure-Specific Devices](https://www.lek.com/industries/medtech/procedure-specific-medical-devices)

[Drug Delivery](https://www.lek.com/industries/life-sciences-pharma/drug-delivery)

#### Capabilities

[Marketing & Sales](https://www.lek.com/capabilities/marketing-and-sales)

[Organization Design and Effectiveness](https://www.lek.com/capabilities/organizational-strategy)

[Performance Improvement](https://www.lek.com/capabilities/performance-improvement)

[Strategy](https://www.lek.com/capabilities/strategy)

[Value Activation](https://www.lek.com/capabilities/organizational-strategy/value-activation)

[Go-to-Market and Commercial Organization](https://www.lek.com/capabilities/marketing-and-sales/go-to-market-strategy)

[Corporate Strategy](https://www.lek.com/capabilities/strategy/corporate-strategy)

Read more

### Related Insights

[Special Report\\
\\
\\
**Life Sciences & Pharma****Prescription for Progress: A Health Equity Maturity Framework for Pharma Companies**\\
\\
June 12, 2025](https://www.lek.com/insights/hea/eu/sr/prescription-progress-health-equity-maturity-framework-pharma-companies)

[Executive Insights\\
\\
\\
**Life Sciences & Pharma****When Is It Too Late? Drivers of Commercial Performance for Late Entrants in Biopharma**\\
\\
April 28, 2025](https://www.lek.com/insights/hea/us/ei/when-it-too-late-drivers-commercial-performance-late-entrants-biopharma)

[Case Study\\
\\
\\
**Biotech and Pharmaceuticals****Reimbursement Assessment for a Therapy for Hemodialysis Patients**\\
\\
May 3, 2024\\
\\
A biopharmaceutical company with a novel treatment of chronic kidney disease-associated pruritus asked L.E.K. to assess the potential risk of bundling of…](https://www.lek.com/insights/hea/eu/cs/reimbursement-assessment-therapy-hemodialysis-patients)

[Case Study\\
\\
\\
**Biotech and Pharmaceuticals****Pricing Strategy for a Recently Commercialized Rheumatoid Arthritis Drug**\\
\\
April 30, 2024\\
\\
A biopharma company with a recently launched rheumatoid arthritis drug asked L.E.K. Consulting to define the optimal price strategies for the 12-18 months…](https://www.lek.com/insights/hea/eu/cs/pricing-strategy-recently-commercialized-rheumatoid-arthritis-drug)

[Video / Webinar\\
\\
\\
**Life Sciences & Pharma****The Need for Launch Planning**\\
\\
April 25, 2024](https://www.lek.com/insights/hea/global/vd/need-launch-planning)

[Video / Webinar\\
\\
\\
**Biotech and Pharmaceuticals****Launch Excellence for Biopharma: Planning for Success**\\
\\
March 8, 2023](https://www.lek.com/insights/hea/us/vd/launch-excellence-biopharma-planning-success)

- [Load more](https://www.lek.com/leadership/christian-seiffert?page=1 "Load more items")

Previous

### Launch Excellence for Biopharma: Planning for Success

![](https://fast.wistia.com/embed/medias/ebtqmq74gy/swatch)

![Video Thumbnail](https://fast.wistia.com/embed/medias/ebtqmq74gy/swatch)

![Video Thumbnail](https://embed-ssl.wistia.com/deliveries/d9de972ed61e70ae74a02042b888c821.webp?image_crop_resized=1920x1080)

Click for sound

4:26

### The Need for Launch Planning

![](https://fast.wistia.com/embed/medias/6hfn5ij0bj/swatch)

![Video Thumbnail](https://fast.wistia.com/embed/medias/6hfn5ij0bj/swatch)

![Video Thumbnail](https://embed-ssl.wistia.com/deliveries/e3a8d5d509acfd32e44583f18b372b40.webp?image_crop_resized=1920x1080)

Click for sound

4:45

Next

![launch excellence ](https://www.lek.com/sites/default/files/teaser-images/launch-excellence-biopharma_teaser.jpg)

##### Biotech and Pharmaceuticals

#### Launch Excellence for Biopharma: Planning for Success

![teaser image](https://www.lek.com/sites/default/files/teaser-images/launch-planning-teaser.jpg)

##### Life Sciences & Pharma

#### The Need for Launch Planning

First name

Last name

Email

Phone number

My locationUnited StatesCanadaAfghanistanAlbaniaAlgeriaAmerican SamoaAndorraAngolaAnguillaAntarcticaAntigua and BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBosnia and HerzegovinaBotswanaBrazilBritish Indian Ocean TerritoryBritish Virgin IslandsBruneiBulgariaBurkina FasoBurundiCambodiaCameroonCape VerdeCayman IslandsCentral African RepublicChadChileChinaChristmas IslandCocos (Keeling) IslandsColombiaComorosCongoCook IslandsCosta RicaCroatiaCubaCuraçaoCyprusCzech RepublicCôte d’IvoireDemocratic Republic of the CongoDenmarkDjiboutiDominicaDominican RepublicEcuadorEgyptEl SalvadorEquatorial GuineaEritreaEstoniaEthiopiaFalkland IslandsFaroe IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHondurasHong Kong S.A.R., ChinaHungaryIcelandIndiaIndonesiaIranIraqIrelandIsle of ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKuwaitKyrgyzstanLaosLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacao S.A.R., ChinaMacedoniaMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorth KoreaNorthern Mariana IslandsNorwayOmanPakistanPalauPalestinian TerritoryPanamaPapua New GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto RicoQatarRomaniaRussiaRwandaRéunionSaint BarthélemySaint HelenaSaint Kitts and NevisSaint LuciaSaint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra LeoneSingaporeSlovakiaSloveniaSolomon IslandsSomaliaSouth AfricaSouth KoreaSouth SudanSpainSri LankaSudanSurinameSvalbard and Jan MayenSwazilandSwedenSwitzerlandSyriaTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos IslandsTuvaluU.S. Virgin IslandsUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor Outlying IslandsUruguayUzbekistanVanuatuVaticanVenezuelaViet NamWallis and FutunaWestern SaharaYemenZambiaZimbabwe

Reason for contactingBusiness - I'm exploring hiring L.E.K.Press - I'm a media representative seeking an L.E.K. expert perspectiveCareer - I'm exploring working at L.E.K.Events - I'm looking to invite L.E.K. to participate in an upcoming eventOther

Company

Message

Comments

By clicking “Contact me” I acknowledge and agree to the L.E.K. Consulting [Privacy Notice](https://www.lek.com/lek-consulting-privacy-policy).

×